Recent Updates
Recently added Catalysts
SRRK Positive Sentiment

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Wednesday, September 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Scholar Rock has received Fast Track and Orphan Drug designations from the FDA for its drug apitegromab, aimed at treating facioscapulohumeral muscular dystrophy (FSHD). The company has also initiated participant dosing in the Phase 2 FORGE trial. This development highlights the potential of apitegromab in addressing a significant unmet medical need.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA granted Fast Track designation to apitegromab.
  • Orphan Drug designation received for FSHD treatment.
  • Dosing for Phase 2 FORGE trial has commenced.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+68%
120-day peak, hindsight
Typical move
8.7%
average across 5 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
Apitegromab
Phase 3 · Spinal Muscular Atrophy

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA has granted Fast Track and Orphan Drug designations to apitegromab for the treatment of people living with FSHD. In addition, the Company announced that participant dosing is underway in the Phase 2 FORGE c

Frequently Asked Questions

What designations did Scholar Rock receive for apitegromab?

Scholar Rock received FDA Fast Track and Orphan Drug designations for apitegromab.

What condition is apitegromab targeting?

Apitegromab is targeting facioscapulohumeral muscular dystrophy (FSHD).

What trial is currently underway for apitegromab?

The Phase 2 FORGE trial is currently underway for apitegromab.

Where is Scholar Rock based?

Scholar Rock is based in Cambridge, Massachusetts.

ShareAdd on Google
Tags: SRRK Viatris Investor Conferences Healthcare Scholar Rock apitegromab FSHD FDA Fast Track Orphan Drug
Last updated: Sep 2, 2026

Biotech snapshot

Cash runway
$492M liquidity · $23M/mo burn
~20 mo
Low dilution risk
Lead asset
ApitegromabPhase 3
Spinal Muscular Atrophy →

Catalyst track record

+68%
best trade around SRRK's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for SRRK.

See every catalyst's timing & PoA →